Regulation of transmitter release by high-affinity group III mGluRs in the supraoptic nucleus of the rat hypothalamus.
We analyzed the subtypes of group III metabotropic glutamate receptors (mGluRs) modulating inhibitory and excitatory transmission in the rat supraoptic nucleus. Bath application of the agonist l-AP4 at 200 microM, a concentration that activates all group III mGluR subtypes, inhibited the frequency but not the amplitude of miniature inhibitory and excitatory postsynaptic currents, indicating a presynaptic site of action. l-AP4 at low concentrations (10 microM), as well as ACPT-1 (50 microM), a specific mGluR III agonist, inhibited transmission at GABAergic and glutamatergic synapses to the same extent as 200 microM l-AP4. Because the potency of l-AP4 and ACPT-1 is much higher on mGluR4 and mGluR8 than on mGluR7, these results are consistent with the presence of high-affinity group III mGluRs regulating transmitter release in this nucleus. In agreement with these findings, DCPG (30 microM), a selective mGluR8 agonist, induced a significant depression of inhibitory and excitatory synaptic currents. Group III mGluRs such as mGluR8, because of their high affinity for glutamate, are particularly well suited to detect small changes in the concentration of this excitatory amino acid in the extracellular space. Their presence, therefore, may favor the negative feedback control exerted by glutamate on its own release as well as the intersynaptic crosstalk mediated by glutamate spillover on adjacent synapses.
Panatier
Aude
A
Inserm U378, Institut François Magendie, Université Victor Segalen, 1, rue Camille Saint Saëns, 33077 Bordeaux Cedex, France.
Poulain
Dominique A
DA
Oliet
Stéphane H R
SH
D000613:Aminobutyrates / Q000494:pharmacology; D000818:Animals; D001565:Benzoates / Q000494:pharmacology; D003517:Cyclopentanes / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D018690:Excitatory Amino Acid Agonists; D019706:Excitatory Postsynaptic Potentials / Q000187:drug effects / Q000502:physiology; D005260:Female; D018698:Glutamic Acid / Q000378:metabolism*; D005998:Glycine / Q000031:analogs & derivatives* / Q000494:pharmacology; D066298:In Vitro Techniques; D008297:Male; D008564:Membrane Potentials / Q000187:drug effects; D009433:Neural Inhibition / Q000187:drug effects; D009474:Neurons / Q000187:drug effects / Q000378:metabolism*; D018408:Patch-Clamp Techniques / Q000379:methods; D051381:Rats; D017208:Rats, Wistar; D018094:Receptors, Metabotropic Glutamate / Q000378:metabolism*; D013495:Supraoptic Nucleus / Q000166:cytology* / Q000187:drug effects; D009435:Synaptic Transmission / Q000187:drug effects / Q000502:physiology*; D014233:Tricarboxylic Acids / Q000494:pharmacology; D005680:gamma-Aminobutyric Acid / Q000378:metabolism*
C409063:1-aminocyclopentane-1,2,4-tricarboxylic acid; C110733:3,4-dicarboxyphenylglycine; D000613:Aminobutyrates; D001565:Benzoates; D003517:Cyclopentanes; D018690:Excitatory Amino Acid Agonists; D018094:Receptors, Metabotropic Glutamate; D014233:Tricarboxylic Acids; C102718:metabotropic glutamate receptor 3; D018698:Glutamic Acid; D005680:gamma-Aminobutyric Acid; C012729:2-amino-4-phosphonobutyric acid; D005998:Glycine